Takeda Reports FY2024 Results & FY2025 Growth Outlook
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal…
Read MoreTakeda Reports FY2024 Results & FY2025 Growth Outlook
Final Phase 3 MYR301 Data: Longer Bulevirtide Use Sustains Undetectability Post-Treatment
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from…
New EASL 2025 Data: Gilead’s Livdelzi® (Seladelpar) Effective and Safe Regardless of Prior Treatments
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment…
Enhertu + THP Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab,…
Novo Nordisk Reports 19% Sales Growth to DKK 78.1 Billion in Q1 2025
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange…
Roche Launches Elecsys PRO-C3 Test to Enhance Accuracy in Liver Fibrosis Assessment
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its Elecsys® PRO-C3 test, a new diagnostic tool developed in collaboration with Nordic Bioscience, to assess the severity of…
Health Inequities Are Cutting Lives Short by Decades
Global Health Inequities Slashing Lifespans by Decades, WHO Warns A new report by the World Health Organization (WHO) reveals that the root causes of poor health often lie outside the…
Teva and Alvotech Receive FDA Approval for SELARSDI™ as an Interchangeable Biosimilar to Stelara
Teva and Alvotech Expand U.S. Biosimilar Portfolio with Approval for SELARSDI™ Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) have…
WHO Reminds Us: Gloves Are No Replace for Hand Hygiene
WHO Highlights the Importance of Hand Hygiene Over Gloves on World Hand Hygiene Day Hand hygiene remains one of the most effective, affordable, and universal tools in preventing the spread…
Johnson & Johnson Unveils Oncology Care Index, Exposing Gaps Between Cancer Innovation and Real-World Practice
73% of healthcare professionals (HCPs) report a disconnect between the availability of cutting-edge treatments and their effective implementation in clinical practice, while 3 in 4 oncologists say the rapid pace…
TREMFYA® Sustains Remission in Ulcerative Colitis Through Two Years
TREMFYA® Shows Sustained Long-Term Remission in Ulcerative Colitis Patients, According to Phase 3 QUASAR LTE Study More than 70% of patients in clinical remission and over 40% in endoscopic remission…
GSK advances the future of respiratory medicine and patient care with new data presented at ATS
GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking…